ERBB2 and breast cancer: In the meantime, mAb immunogenicity had been reduced by the introduction of chimeric, humanized or human antibodies [7] and targeted therapies using high amounts of naked mAbs experienced an important development in hematology with the anti-CD20 rituximab in B non-Hodgkin lymphoma (NHL) and oncology with the anti-HER2 trastuzumab in breast carcinoma (BC) [8,9].